BioLine Rx Analyst Price Targets - Benzinga

BioLine Rx Ltd

BLRXNASDAQ

Trade with Public

Trade with Public

$2.19

0.0150.69%

Ult. Agg.: Oct 13, 1:51 PM

$2.28

0.115.07%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Confronta Opzioni Rapporto azionario

BioLine Rx Analyst Price Targets - Benzinga

BioLine Rx Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioLine Rx (BLRX).

Price Target Range — 7 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$19Upside to Avg. PT+769.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 17, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$26
May 30, 2025	Jones Trading	Justin Walsh	Upgrade	Hold→Buy	$12
May 28, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$26
Apr 2, 2025	Jones Trading	Justin Walsh	Downgrade	Buy→Hold	—
Mar 31, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$9→$26
Nov 25, 2024	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$21→$9
Nov 6, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Sep 4, 2024	Jones Trading	Justin Walsh	Initiate	Buy	$2
Jun 3, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
May 29, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Apr 17, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Mar 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Feb 29, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Nov 20, 2023	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21

More with Benzinga EdgeGet Access

Analyst Ratings News

Where BioLine Rx Stands With Analysts

Benzinga Insights

PRO
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Jones Trading Upgrades BioLine Rx to Buy, Announces $12 Price Target

Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:BLRX) from Hold to Buy and announces $12 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Jones Trading Downgrades BioLine Rx to Hold

Jones Trading analyst Justin Walsh downgrades BioLine Rx (NASDAQ:BLRX) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $26

HC Wainwright & Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $9 to $26.

Benzinga Newsdesk